Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Pembrolizumab in CLL or MCL
NCT03153202Phase 2Active, not recruiting
- Start
- Jul 2017
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL). Started Jul 2017; status: active, not recruiting.
02
Drugs
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03153202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153202.